Ying Xu completed her doctoral studies at Duke University in 2011. Since joining Analytical development and QC department at Sanofi Genzyme, she has progressively taken on increased responsibilities. Currently serving as an Associate Director, Ying provides leadership to two dedicated analytical teams to support both protein and viral vector-based therapeutics throughout early phase development. Ying plays an important role in overseeing method validation, method transfer and GMP sample testing across multiple CROs and CDMOs. Her responsibilities encompass release of cell banks, end of production testing, in-process sample testing to lot release of DS/DP as well as stability studies. Ying serves as a core member of BioPhorum, a forum that brings together SMEs and regulatory experts from various biopharmaceutical companies. She led a discussion focused on minimizing the impact of Container Closure integrity testing on batch yield for cell and gene therapeutics.